Barry MJ, Edgman-Levitan S. Shared decision making pinnacle of patient-centered care. N Engl J Med. 2012;366:780 1. S6-27. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making. 2015;35:114 31. S6-28. Using Motivational Interviewing to Create Change. Available at: http:// tCookieSupport=1. Accessed March 27, 2018. 7. COST AND VALUE CONSIDERATIONS 7.1. Economic Value Considerations: S7.1-1. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. S7.1-2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clini- cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713 22. S7.1-3. Hlatky MA, Kazi DS. PCSK9 Inhibitors: economics and policy. J Am Coll Cardiol. 2017;70:2677 87. S7.1-4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267 78. S7.1-5. Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evo- locumab therapy for reducing cardiovascular events in patients with ath- erosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069 78. S7.1-6. Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412 21. S7.1-7. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercho- lesaaaaaaaaterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743 53. S7.1-8. Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39:313 20. S7.1-9. 